Personalis Expands Breast Cancer Coverage with NeXT Personal
Personalis, Inc. has announced that the Centers for Medicare & Medicaid Services has expanded coverage for its NeXT Personal minimal residual disease test to include monitoring treatment response for patients with Stage II-III Triple-Negative Breast Cancer undergoing neoadjuvant therapy.
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company’s NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Canc